Drug Profile
Research programme: immune system stimulants - Pulmotect
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pulmotect
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunocompromised infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Immunocompromised-infections(Prevention) in USA
- 09 May 2012 Preclinical trials in Immunocompromised infections (prevention) in USA (unspecified route)